A novel approach of prophylaxis to HBV recurrence after liver transplantation

Virology

Volumn 382, Issue 1, 2008, Pages 1-9

  Pan, Tao ^a   Cai, Ming ^a   Tang, Li ^b   Zhou, Li Qiao ^c   Li, Bin Jian ^c   Zhu, Tong ^c   Li, Hong Zhou ^a   Li, Shu Yuan ^a   Xiao, Xiao ^c   Chen, Zhi Shui ^a  

^a BEIJING HOSPITAL   (China)

^b NINGBO UNIVERSITY   (China)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Adeno associated virus; Hepatitis B virus; Humanized antibody

Indexed keywords

ANTIVIRUS AGENT; HBSAG ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; HEPATITIS B; HEPATITIS B VIRUS; IMMUNOPROPHYLAXIS; LIVER TRANSPLANTATION; MOLECULAR CLONING; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; BASE SEQUENCE; CHEMOPREVENTION; DEPENDOVIRUS; GENE THERAPY; GENETIC VECTORS; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VIRUS; HUMANS; LIVER TRANSPLANTATION; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; RECURRENCE; TUPAIIDAE;

ADENO-ASSOCIATED VIRUS; HEPATITIS B VIRUS; TUPAIIDAE;

EID: 55549142502     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2008.06.024     Document Type: Article

References (55)

1. Anderson R.D., Chinnakotla S., Guo L., Perrillo R.P., Klintmalm G.B., and Davis G.L. Intramuscular hepatitis B immunoglobulin (HBIG) and nucleosides for prevention of recurrent hepatitis B following liver transplantation: comparison with other HBIG regimens. Clin. Transplant. 21 (2007) 510-517
2. Andre F. Hepatitis B epidemiology in Asia, the Middle East and Africa. Vaccine 18 Suppl 1 (2000) 20-22
3. Becker W., Goldenberg D.M., and Wolf F. The use of monoclonal antibodies and antibody fragments in the imaging of infectious lesions. Semin. Nucl. Med. 24 (1994) 142-153
4. Beckebaum S., Cicinnati V.R., and Gerken G. Current concepts for prophylaxis and treatment of hepatitis B virus reinfection after liver transplantation. Med. Klin. 103 (2008) 190-197
5. Blum H.E., Wieland S., Walter E., Weizsacker F., Offensperger W.-B., and Moradpour D. Nature course of HBV infection. In: Koshy R., and Caselmann W.H. (Eds). Hepatitis B Virus. Molecular Mechanisms in Disease and Novel Strategies for Therapy (1998), Imperial College Press, London, United Kingdom 75-92
6. Brown K.A., and Moonka D.K. Liver transplantation. Curr. Opin. Gastroenterol. 16 (2000) 290-294
7. Boder E.T., and Wittrup K.D. Yeast surface display for directed evolution of protein expression, affinity, and stability. Methods Enzymol. 328 (2000) 430-444
8. Chen H.B., Fang D.X., Li F.Q., Jing H.Y., Tan W.G., and Li S.Q. A novel hepatitis B virus mutant with A-to-G at nt551 in the surface antigen gene. World. J. Gastroenterol. 9 (2003) 304-308
9. Coffin C.S., and Terrault N.A. Management of hepatitis B in liver transplant recipient. J. Viral. Hepa. 4 suppl 1 (2007) 37-44
10. Dandri M., Burda M.R., Török E., Pollok J.M., Iwanska A., Sommer G., Rogiers X., Rogler C.E., Gupta S., Will H., Greten H., and Petersen J. Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatology 33 (2001) 981-988
11. Dandri M., Burda M.R., Zuckerman D.M., Wursthorn K., Matschl U., Pollok J.M., Rogiers X., Gocht A., Köck J., Blum H.E., von Weizsäcker F., and Petersen J. Chronic infection with hepatitis B viruses and antiviral drug evaluation in uPA mice after liver repopulation with Tupaia hepatocytes. J. Hepatol. 42 (2005) 54-60
12. Dandri M., Lutgehetmann M., Volz T., and Petersen J. Small animal model systems for studying hepatitis B virus replication and pathogenesis. Semin. Liver Dis. 26 (2006) 181-191
13. Di P.G., Davidson B.L., Stein C.S., Martins I., Scudiero D., Monks A., and Chiorini J.A. Identification of PDGFR as a receptor for AAV-5 transduction. Nat. Med. 9 (2003) 1306-1312
14. Ehrlich P.H., Moustafa Z.A., Justice J.C., Harfeldt K.E., Kelley R.L., and Ostberg L. Characterization of human monoclonal antibodies directed against hepatitis B surface antigen. Hum. Antibodies Hybridomas. 3 (1992) 2-7
15. Freshwater, D.A., Dudley, T., Cane, P., Mutimer, D.J., 2008. Viral persistence after liver transplantation for hepatitis B virus: a cross-sectional study. 85, 1105-1111
16. Gao G.P., Alvira M.R., Wang L., Calcedo R., Johnston J., and Wilson J.M. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. 99 (2002) 11854-11859
17. Glebe D., Aliakbari M., Krass P., Knoop E.V., Valerius K.P., and Gerlich W.H. Pre-s1 antigen-dependent infection of Tupaia hepatocyte cultures with human hepatitis B virus. J. Virol. 77 (2003) 9511-9521
18. Habib S., and Shaikh O.S. Hepatitis B immune globulin. Drug Today (Barc). 43 (2007) 379-394
19. Hollinger F.B. Hepatitis B vaccines-to switch or not to switch. J. Am. Med. Assoc. 257 (1987) 2634-2636
20. Hong H.J., Ryu C.J., Hur H., Kim S., Oh H.K., Oh M.S., and Park S.Y. In vivo neutralization of hepatitis B virus infection by an anti-preS1 humanized antibody in chimpanzees. Virology 318 (2004) 134-141
21. Johnstone A., and Thorpe R. Affinity purification methods. Immunochemistry in Practice (1982), Blachwell Scientific Publication, Oxford, United Kingdom 905-909
22. Kane M.A. Global status of hepatitis B immunization. Lancet 348 (1996) 696
23. Kozak M. Possible role of flanking nucleotides in recognition of the AUG initiator codon by eukaryotic ribosome. Nucleic Acids Res. 9 (1981) 5233-5525
24. Köck J., Nassal M., MacNelly S., Baumert T.F., Blum H.E., and von Weizsäcker F. Efficient infection of primary Tupaia hepatocytes with purified human and woolly monkey hepatitis B virus. J. Virol. 75 (2001) 5084-5089
25. Köck J., Baumert T.F., Delaney IV W.E., Blum H.E., and von Weizsäcker F. Inhibitory effect of adefovir and lamivudine on the initiation of hepatitis B virus infection in primary Tupaia hepatocytes. Hepatology 38 (2003) 1408-1410
26. Levy R., and Miller R.A. Tumor therapy with monoclonal antibodies. Fed. Proc. 42 (1983) 2650-2656
27. Lo C.M., Fung J.T., Lau G.K., Liu C.L., Cheung S.T., Lai C.L., and Fan S.T. Development of antibody to hepatitis B surface antigen after liver transplantation for chronic hepatitis B. Hepatology 37 (2003) 36-43
28. Muller R., Gubernatic G., and Farle M. Liver transplantation in HBs antigen (HBsAg) carriers prevention of hepatitis B virus (HBV) recurrence by passive immunization. J. Hapatol. 13 (1991) 90-96
29. Neurath A.R., Kent S.B., Strick N., and Parker K. Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus. Cell 46 (1986) 429-436
30. Protzer-Knolle U., Naumann U., Bartenschlager R., Berg T., Hopf U., and Meyer zum Buschenfelde K.H. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 27 (1998) 254-263
31. Rutledge E.A., Halbert C.L., and Russell D.W. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72 (1998) 309-319
32. Sambrook J., Pritsch E.F., and Maniais T. Molecular Cloning, A Laboratory Manual. 2nd ed. (1989), Cold Spring Harbor Laboratory Press, New York, USA
33. Schiff E., Lai C.L., Hadziyannis S., Neuhaus P., Terrault N., Colombo M., Tillmann H., Samuel D., Zeuzem S., Villeneuve J.P., Arterburn S., Borroto-Esoda K., Brosgart C., Chuck S., and Adefovir Dipivoxil Study 45 Intrnational Investigators Group. T Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine resistant hepatitis B: final long-term results. Liver Transpl. 13 (2007) 349-360
34. Schmitz J., Ohme M., and Zischler H. The complete mitochondrial genome of Tupaia belangeri and the phylogenetic affiliation of Scandentia to other Eutherian orders. Mol. Biol. Evol. 17 (2000) 1334-1343
35. Shin Y.W., Ryoo K.H., Hong K.W., Chang K.H., Choi J.S., So M., Kim P.K., Park J.Y., Bong K.T., and Kim S.H. Human monoclonal antibody against Hepatits B virus surface antigen (HBsAg). Antiviral Research 75 (2007) 113-120
36. Shouval D., and Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology 32 (2000) 1189-1195
37. Snyder R., Xiao X., and Samulski R.J. Production of recombinant adeno-associated viral vectors. In: Dracopoli N., et al. (Ed). Current Protocols in Human Genetics (1996), John Wiley & Sons Ltd, New York 12.11.11-12.12.23
38. Summerford C., and Samulski R.J. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 visions. J. Virol. 72 (1998) 1438-1445
39. Tao P., Tang L., Dong X., Lai W., Changsheng M., and Zhishui C. Model of primary human hepatocytes absorption with HBsAg and infection with HBV. Acta. Med. Univ. Sci. Technol. Huazhong. (2006) 479-482 Aug
40. Tao P., Li T., Jin Y., Nianqiao G., Dawei W., Dunxiu C., Hui G., and Zhishui C. Recombinant anti-HBsAg Fab blocks hepatitis B virus infection after orthotopic liver transplantation. Hepatobiliary Pancreat. Dis. Int. 6 (2007) 370-375
41. Tapp E., and Jones D.M. HBsAg and HBcAg in the livers of asymptomatic hepatitis B antigen carriers. J. Clinical Pathology 30 (1977) 671-677
42. Tam M.R., and Goldstein L.C. In vitro diagnostic test. in Manual of Clinical Microbiology. In: Lennette E.H., Balows A., and Hausler W.J. (Eds). Am. Soc. Microbiol. (1985) 905-909 Washington, USA
43. Tchervenkov J.I., Tector A.J., Barkun J.S., Sherker A., Forbes C.D., Elias N., Cantarovich M., Cleland P., Metrakos P., and Meakins J.L. Recurrence-free long-term survival after liver transplantation for hepatitis B using interferon-alpha pretransplant and hepatitis B immune globulin posttransplant. Ann. Surg. 226 (1997) 356-365 discussion 365-368
44. Trautwein C. Mechanisms of hepatitis B virus graft reinfection and graft damage after liver transplantation. J. Hepatol. 41 (2004) 362-369
45. von Weizsäcker F., Köck J., MacNelly S., Ren S., Blum H.E., and Nassal M. The Tupaia model for the study of hepatitis B virus: direct infection and HBV genome transduction of primary Tupaia hepatocytes. Methods Mol. Med. 96 (2004) 153-161
46. Walter E., Keist R., Niederost B., Pult I., and Blum H.E. Hepatitis B virus infection of Tupaia hepatocytes in vitro and in vivo. Hepatology 24 (1996) 1-5
47. Wang S.S., Su J.J., Feng B.F., Li Y., Zhang T., Qin L.L., Huang G.Y., Gao J.E., Ge X.M., and Li H.M. Serial pathologic changes in livers of tree shrews and Macaca assamensises infected with human hepatitis B virus. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 17 (2003) 244-246
48. Witherell G. XTL-001. XTL Pharmaceuticals. Curr. Opin. Investig. Drugs 3 (2002) 684-692
49. Wong S.N., Chu C.J., Wai C.T., Howell T., Moore C., Fontana R.J., and Lok A.S. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos (t) ide analogue therapy. Liver Transpl. 13 (2007) 374-381
50. Xiao X., Li J., and Samulski R.J. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J. Virol. 72 (1998) 2224-2232
51. Yan W., Qunying L., Jianjun Xu., Yaming W., and Jinghua C. Expression and analysis of anti-HBs human Fab derived from phage antibody library. Chin. J. Microbiol. Immunol. 15 (1995) 304-307
52. Yan R.Q., Su J.J., Huang D.R., Gan Y.C., Yang C., and Huang G.H. Human hepatitis B virus and hepatocellular carcinoma. I. Experimental infection of tree shrews with hepatitis B virus. J. Cancer Res. Clin. Oncol. 122 (1996) 283-288
53. Yan W., Yuxiao W., Yingchun Z., Xiaolin L., Hairong Z., Qunying L., Bing H., Xiaosui C., and Yuping C. Conversion of anti-HBs human Fab derived from phage antibody library to whole human IgG molecules. Chin. J. Microbiol. Immunol. 20 (2000) 41-44
54. Yang E.B., Cao J., Su J.J., and Chow P. The tree shrew: useful animal models for the viral hepatitis and hepatocellular carcinoma. Hepatogastroenterology 52 (2005) 613-616
55. Zheng D.Y., Luo R.C., and Cai H.B. Conditions for large-scale production of genetically engineered E. coli bearing humanized anti-HBsAg Fab. Di Yi Jun Yi Da Xue Xue Bao 24 (2004) 517-520